Intravitreal pegaptanib for refractory macular edema secondary to retinal vein occlusion

PURPOSE: To assess the efficacy of intravitreal Pegaptanib sodium (Macugen(®)) injection in the management of refractory macular edema secondary to branch retinal vein occlusion. METHODS: This is a prospective, nonrandomized, interventional case series. Five eyes of five patients with macular edema...

Descripción completa

Detalles Bibliográficos
Autores principales: Udaondo, Patricia, Garcia-Delpech, Salvador, Salom, David, Garcia-Pous, Maria, Diaz-Llopis, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3141857/
https://www.ncbi.nlm.nih.gov/pubmed/21792283
http://dx.doi.org/10.2147/OPTH.S18873
Descripción
Sumario:PURPOSE: To assess the efficacy of intravitreal Pegaptanib sodium (Macugen(®)) injection in the management of refractory macular edema secondary to branch retinal vein occlusion. METHODS: This is a prospective, nonrandomized, interventional case series. Five eyes of five patients with macular edema refractory to either bevacizumab or triamcinolone were treated with intravitreal injection of Pegaptanib sodium. RESULTS: After three months follow-up, both visual acuity and macular edema, measured by optical coherence tomography and fluorescence angiography, dramatically improved. CONCLUSION: Pegaptanib sodium is a safe and efficacy treatment for macular edema secondary to branch retinal vein occlusion.

Ejemplares similares